In another retrospectively study of 123 patients with NSCLC treated with nivolumab or pembrolizumab in Japan, 18 patients (14.6%) experienced anti-PD-1-related pneumonitis, of which four (3.3%) were grade ≥3 (Jodai et al., 2018). Here, PDCD1 is linked to pneumonitis.